Stephen R Cole

List of Publications by Year in Descending Order

209 papers	11,350 citations	46 h-index	104 g-index
219 ext. papers	13,440 ext. citations	4.4 avg, IF	6.64 L-index

#	Paper	IF	Citations
209	Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy.. *Aids*, **2022**, 36, 277-286	3.5	2
208	A new smoking cessation Rascade Among women with or at risk for HIV infection. *Aids*, **2022**, 36, 107-116	3.5	
207	Introduction to computational causal inference using reproducible Stata, R, and Python code: A tutorial. *Statistics in Medicine*, **2021**,	2.3	3
206	Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. *Journal of Infectious Diseases*, **2021**, 224, 657-666	7	1
205	Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. *Clinical Infectious Diseases*, **2021**, 73, e1408-e1414	11.6	3
204	Fusion designs and estimators for treatment effects. *Statistics in Medicine*, **2021**, 40, 3124-3137	2.3	2
203	Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005-2015. *Aids*, **2021**, 35, 1229-1239	3.5	
202	Revisiting Overadjustment Bias. *Epidemiology*, **2021**, 32, e22-e23	3.1	2
201	Transportability From Randomized Trials to Clinical Care: On Initial HIV Treatment With Efavirenz and Suicidal Thoughts or Behaviors. *American Journal of Epidemiology*, **2021**, 190, 2075-2084	3.8	0
200	Decreased Susceptibility of Marginal Odds Ratios to Finite-sample Bias. *Epidemiology*, **2021**, 32, 648-652	3.1	2
199	HIV viral exposure and mortality in a multicenter ambulatory HIV adult cohort, United States, 1995-2016. *Medicine (United States)*, **2021**, 100, e26285	1.8	
198	Maternal HIV Infection and Spontaneous Versus Provider-Initiated Preterm Birth in an Urban Zambian Cohort. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2021**, 87, 860-868	3.1	0
197	G-computation for policy-relevant effects of interventions on time-to-event outcomes. *International Journal of Epidemiology*, **2021**, 49, 2021-2029	7.8	5
196	Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features. *JNCI Cancer Spectrum*, **2021**, 5, pkaa072	4.6	3
195	Comparing Parametric, Nonparametric, and Semiparametric Estimators: The Weibull Trials. *American Journal of Epidemiology*, **2021**, 190, 1643-1651	3.8	1
194	Is OR "portable" in meta-analysis? Time to consider bivariate generalized linear mixed model. *Journal of Clinical Epidemiology*, **2021**,	5.7	2
193	Poverty, Deprivation, and Mortality Risk Among Women With HIV in the United States. *Epidemiology*, **2021**, 32, 877-885	3.1	1

192	Odds ratios are far from "portable"-A call to use realistic models for effect variation in meta-analysis. *Journal of Clinical Epidemiology*, **2021**,	5.7	3
191	Ensemble estimation and variable selection with semiparametric regression models. *Biometrika*, **2020**, 107, 433-448	2	1
190	Flexibly Accounting for Exposure Misclassification With External Validation Data. *American Journal of Epidemiology*, **2020**, 189, 850-860	3.8	1
189	Standardizing Discrete-Time Hazard Ratios With a Disease Risk Score. *American Journal of Epidemiology*, **2020**, 189, 1197-1203	3.8	1
188	Fermat Passage. *Epidemiology*, **2020**, 31, e47	3.1	
187	Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors. *PLoS ONE*, **2020**, 15, e0242405	3.7	1
186	Neighborhood Poverty and Control of HIV, Hypertension, and Diabetes in the Women Interagency HIV Study. *AIDS and Behavior*, **2020**, 24, 2033-2044	4.3	2
185	Assessing Exposure-Response Trends Using the Disease Risk Score. *Epidemiology*, **2020**, 31, e15-e16	3.1	2
184	Two-stage g-computation: Evaluating Treatment and Intervention Impacts in Observational Cohorts When Exposure Information Is Partly Missing. *Epidemiology*, **2020**, 31, 695-703	3.1	0
183	Remdesivir and COVID-19. *Lancet, The*, **2020**, 396, 953	40	6
182	Estimating a Set of Mortality Risk Functions with Multiple Contributing Causes of Death. *Epidemiology*, **2020**, 31, 704-712	3.1	1
181	Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors **2020**, 15, e0242405		
180	Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors **2020**, 15, e0242405		
179	Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors **2020**, 15, e0242405		
178	Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors **2020**, 15, e0242405		
177	Using Animations of Risk Functions to Visualize Trends in US All-Cause and Cause-Specific Mortality, 1968-2016. *American Journal of Public Health*, **2019**, 109, 451-453	5.1	1
176	Nonparametric Bounds for the Risk Function. *American Journal of Epidemiology*, **2019**, 188, 632-636	3.8	3
175	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. *American Journal of Epidemiology*, **2019**, 188, 1569-1577	3.8	45

174	Proximal HbA1C Level and First Hypoglycemia Hospitalization in Adults With Incident Type 2 Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 1989-1998	5.6	1
173	Safety of Dynamic Intravenous Iron Administration Strategies in Hemodialysis Patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2019**, 14, 728-737	6.9	18
172	Using Bounds to Compare the Strength of Exchangeability Assumptions for Internal and External Validity. *American Journal of Epidemiology*, **2019**, 188, 1355-1360	3.8	7
171	Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial. *BMC Pregnancy and Childbirth*, **2019**, 19, 81	3.2	4
170	Marginal Structural Models for Risk or Prevalence Ratios for a Point Exposure Using a Disease Risk Score. *American Journal of Epidemiology*, **2019**, 188, 960-966	3.8	5
169	Survival of infants with spina bifida and the role of maternal prepregnancy body mass index. *Birth Defects Research*, **2019**, 111, 1205-1216	2.9	4
168	Nonparametric estimation of the cumulative incidence function under outcome misclassification using external validation data. *Statistics in Medicine*, **2019**, 38, 5512-5527	2.3	2
167	Estimating Human Immunodeficiency Virus (HIV) Prevention Effects in Low-incidence Settings. *Epidemiology*, **2019**, 30, 358-364	3.1	4
166	Prevalence and 1-year incidence of frailty among women with and without HIV in the Women's Interagency HIV Study. *Aids*, **2019**, 33, 357-359	3.5	9
165	Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV. *AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV*, **2019**, 31, 505-512	2.2	2
164	Target Validity and the Hierarchy of Study Designs. *American Journal of Epidemiology*, **2019**, 188, 438-443	3.8	51
163	Comparison of Methods to Generalize Randomized Clinical Trial Results Without Individual-Level Data for the Target Population. *American Journal of Epidemiology*, **2019**, 188, 426-437	3.8	13
162	The Effects of Hepatitis C Infection and Treatment on All-cause Mortality Among People Living With Human Immunodeficiency Virus. *Clinical Infectious Diseases*, **2019**, 68, 1152-1159	11.6	4
161	Generalizing the per-protocol treatment effect: The case of ACTG A5095. *Clinical Trials*, **2019**, 16, 52-62	2.2	6
160	Quantifying bias between reported last menstrual period and ultrasonography estimates of gestational age in Lusaka, Zambia. *International Journal of Gynecology and Obstetrics*, **2019**, 144, 9-15	4	14
159	Sensitivity Analyses for Misclassification of Cause of Death in the Parametric G-Formula. *American Journal of Epidemiology*, **2018**, 187, 1808-1816	3.8	5
158	Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights. *Journal of the Royal Statistical Society Series A: Statistics in Society*, **2018**, 181, 1193-1209	2.1	45
157	When to Censor?. *American Journal of Epidemiology*, **2018**, 187, 623-632	3.8	24

156	Empirical Comparison of Publication Bias Tests in Meta-Analysis. *Journal of General Internal Medicine*, **2018**, 33, 1260-1267	4	84
155	RESOLVING AN APPARENT PARADOX IN DOUBLY ROBUST ESTIMATORS. *American Journal of Epidemiology*, **2018**, 187, 891-892	3.8	9
154	Principled Approaches to Missing Data in Epidemiologic Studies. *American Journal of Epidemiology*, **2018**, 187, 568-575	3.8	96
153	Exploring the Subtleties of Inverse Probability Weighting and Marginal Structural Models. *Epidemiology*, **2018**, 29, 352-355	3.1	10
152	Multiple Imputation for Incomplete Data in Epidemiologic Studies. *American Journal of Epidemiology*, **2018**, 187, 576-584	3.8	74
151	Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy. *Aids*, **2018**, 32, 653-661	3.5	1
150	Inverse Probability Weights for the Analysis of Polytomous Outcomes. *American Journal of Epidemiology*, **2018**, 187, 1125-1127	3.8	0
149	Inverse-Probability-Weighted Estimation for Monotone and Nonmonotone Missing Data. *American Journal of Epidemiology*, **2018**, 187, 585-591	3.8	18
148	Primary non-adherence and the new-user design. *Pharmacoepidemiology and Drug Safety*, **2018**, 27, 361-364	2.6	11
147	Asbestos standards: Impact of currently uncounted chrysotile asbestos fibers on lifetime lung cancer risk. *American Journal of Industrial Medicine*, **2018**, 61, 383-390	2.7	6
146	Chlamydia trachomatis Seroprevalence and Ultrasound-Diagnosed Uterine Fibroids in a Large Population of Young African-American Women. *American Journal of Epidemiology*, **2018**, 187, 278-286	3.8	3
145	HbA variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: A nested case-control study. *Journal of Diabetes and Its Complications*, **2018**, 32, 203-209	3.2	17
144	Estimating multiple time-fixed treatment effects using a semi-Bayes semiparametric marginal structural Cox proportional hazards regression model. *Biometrical Journal*, **2018**, 60, 100-114	1.5	1
143	Comparing neighborhood and state contexts for women living with and without HIV: understanding the Southern HIV epidemic. *AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV*, **2018**, 30, 1360-1367	2.2	6
142	Cancer risk in HIV patients with incomplete viral suppression after initiation of antiretroviral therapy. *PLoS ONE*, **2018**, 13, e0197665	3.7	5
141	Association of Household Opioid Availability and Prescription Opioid Initiation Among Household Members. *JAMA Internal Medicine*, **2018**, 178, 102-109	11.5	33
140	Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens. *Aids*, **2018**, 32, 261-266	3.5	8
139	At-Risk Alcohol Use Among HIV-Positive Patients and the Completion of Patient-Reported Outcomes. *AIDS and Behavior*, **2018**, 22, 1313-1322	4.3	3

138	Generalizing Randomized Clinical Trial Results: Implementation and Challenges Related to Missing Data in the Target Population. *American Journal of Epidemiology*, **2018**, 187, 817-827	3.8	16
137	Beyond binary retention in HIV care: predictors of the dynamic processes of patient engagement, disengagement, and re-entry into care in a US clinical cohort. *Aids*, **2018**, 32, 2217-2225	3.5	23
136	Parametric assumptions equate to hidden observations: comparing the efficiency of nonparametric and parametric models for estimating time to AIDS or death in a cohort of HIV-positive women. *BMC Medical Research Methodology*, **2018**, 18, 142	4.7	3
135	Sensitivity analyses for effect modifiers not observed in the target population when generalizing treatment effects from a randomized controlled trial: Assumptions, models, effect scales, data scenarios, and implementation details. *PLoS ONE*, **2018**, 13, e0208795	3.7	14
134	The Authors Respond. *Epidemiology*, **2018**, 29, e14-e15	3.1	2
133	Evaluating the Population Impact on Racial/Ethnic Disparities in HIV in Adulthood of Intervening on Specific Targets: A Conceptual and Methodological Framework. *American Journal of Epidemiology*, **2018**, 187, 316-325	3.8	9
132	US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials. *Clinical Infectious Diseases*, **2017**, 65, 324-327	11.6	15
131	Generalizing Study Results: A Potential Outcomes Perspective. *Epidemiology*, **2017**, 28, 553-561	3.1	116
130	Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States. *Clinical Infectious Diseases*, **2017**, 64, 1591-1596	11.6	9
129	Dietary intake and risk of non-severe hypoglycemia in adolescents with type 1 diabetes. *Journal of Diabetes and Its Complications*, **2017**, 31, 1340-1347	3.2	10
128	Effects of Antiretroviral Therapy and Depressive Symptoms on All-Cause Mortality Among HIV-Infected Women. *American Journal of Epidemiology*, **2017**, 185, 869-878	3.8	27
127	Randomized Controlled Trial of an Intervention to Maintain Suppression of HIV Viremia After Prison Release: The imPACT Trial. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2017**, 75, 81-90	3.1	31
126	Stressful and traumatic life events as disruptors to antiretroviral therapy adherence. *AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV*, **2017**, 29, 1378-1385	2.2	6
125	Transportability of Trial Results Using Inverse Odds of Sampling Weights. *American Journal of Epidemiology*, **2017**, 186, 1010-1014	3.8	111
124	Risk factors for delayed antiretroviral therapy initiation among HIV-seropositive patients. *PLoS ONE* , **2017**, 12, e0180843	3.7	6
123	Malaria, malnutrition, and birthweight: A meta-analysis using individual participant data. *PLoS Medicine*, **2017**, 14, e1002373	11.6	25
122	Inverse probability of treatment-weighted competing risks analysis: an application on long-term risk of urinary adverse events after prostate cancer treatments. *BMC Medical Research Methodology* , **2017**, 17, 93	4.7	20
121	Mortality under plausible interventions on antiretroviral treatment and depression in HIV-infected women: an application of the parametric g-formula. *Annals of Epidemiology*, **2017**, 27, 783-789.e2	6.4	8

120	Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study. *Diabetes Care*, **2017**, 40, 1651-1660	14.6	35
119	The Authors Respond. *Epidemiology*, **2017**, 28, e62-e63	3.1	
118	Dogmatists Cannot Learn. *Epidemiology*, **2017**, 28, e10-e11	3.1	2
117	Periodontitis and Non-alcoholic Fatty Liver Disease, a population-based cohort investigation in the Study of Health in Pomerania. *Journal of Clinical Periodontology*, **2017**, 44, 1077-1087	7.7	34
116	Sensitivity analysis for an unobserved moderator in RCT-to-target-population generalization of treatment effects. *Annals of Applied Statistics*, **2017**, 11,	2.1	29
115	Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation. *Aids*, **2017**, 31, 1989-1997	3.5	15
114	Effects of Health Insurance Interruption on Loss of Hypertension Control in Women With and Women Without HIV. *Journal of Women's Health*, **2017**, 26, 1292-1301	3	2
113	Health Insurance Type and Control of Hypertension Among US Women Living With and Without HIV Infection in the Women's Interagency HIV Study. *American Journal of Hypertension*, **2017**, 30, 594-601	2.3	5
112	An introduction to g methods. *International Journal of Epidemiology*, **2017**, 46, 756-762	7.8	80
111	Statistical methods for multivariate meta-analysis of diagnostic tests: An overview and tutorial. *Statistical Methods in Medical Research*, **2016**, 25, 1596-619	2.3	45
110	An Illustration of Inverse Probability Weighting to Estimate Policy-Relevant Causal Effects. *American Journal of Epidemiology*, **2016**, 184, 336-44	3.8	7
109	Brief Report: Estimating Differences and Ratios in Median Times to Event. *Epidemiology*, **2016**, 27, 848-51	3.1	4
108	A Fundamental Equivalence between Randomized Experiments and Observational Studies. *Epidemiologic Methods*, **2016**, 5,	2.2	3
107	A hybrid Bayesian hierarchical model combining cohort and case-control studies for meta-analysis of diagnostic tests: Accounting for partial verification bias. *Statistical Methods in Medical Research*, **2016**, 25, 3015-3037	2.3	10
106	Nondogmatism. *Annals of Epidemiology*, **2016**, 26, 231-3	6.4	2
105	Ongoing life stressors and suicidal ideation among HIV-infected adults with depression. *Journal of Affective Disorders*, **2016**, 190, 322-328	6.6	14
104	Marginal Structural Cox Models with Case-Cohort Sampling. *Statistica Sinica*, **2016**, 26, 509-526	0.7	3
103	Comparing results from multiple imputation and dynamic marginal structural models for estimating when to start antiretroviral therapy. *Statistics in Medicine*, **2016**, 35, 4335-4351	2.3	2

102	Impact of Health Insurance, ADAP, and Income on HIV Viral Suppression Among US Women in the WomenÃ Interagency HIV Study, 2006-2009. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2016**, 73, 307-312	3.1	29
101	Selection Bias Due to Loss to Follow Up in Cohort Studies. *Epidemiology*, **2016**, 27, 91-7	3.1	176
100	Causal Impact: Epidemiological Approaches for a Public Health of Consequence. *American Journal of Public Health*, **2016**, 106, 1011-2	5.1	31
99	The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009-11. *International Journal of Epidemiology*, **2016**, 45, 140-50	7.8	36
98	Exploring racial differences in the obesity gender gap. *Annals of Epidemiology*, **2015**, 25, 420-5	6.4	10
97	Age at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United States. *Clinical Infectious Diseases*, **2015**, 61, 1189-95	11.6	31
96	Ten-year Survival by Race/Ethnicity and Sex Among Treated, HIV-infected Adults in the United States. *Clinical Infectious Diseases*, **2015**, 60, 1700-7	11.6	28
95	Time at risk and intention-to-treat analyses: parallels and implications for inference. *Epidemiology*, **2015**, 26, 112-8	3.1	5
94	Illustration of a measure to combine viral suppression and viral rebound in studies of HIV therapy. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2015**, 68, 241-4	3.1	5
93	Estimation of the standardized risk difference and ratio in a competing risks framework: application to injection drug use and progression to AIDS after initiation of antiretroviral therapy. *American Journal of Epidemiology*, **2015**, 181, 238-45	3.8	34
92	Imputation approaches for potential outcomes in causal inference. *International Journal of Epidemiology*, **2015**, 44, 1731-7	7.8	20
91	Self-Reported Reproductive Tract Infections and Ultrasound Diagnosed Uterine Fibroids in African-American Women. *Journal of WomenÃs Health*, **2015**, 24, 489-95	3	12
90	Outcomes of pharmacist-assisted management of antiretroviral therapy in patients with HIV infection: A risk-adjusted analysis. *American Journal of Health-System Pharmacy*, **2015**, 72, 1463-70	2.2	11
89	Multiple Imputation to Account for Measurement Error in Marginal Structural Models. *Epidemiology* , **2015**, 26, 645-52	3.1	12
88	All your data are always missing: incorporating bias due to measurement error into the potential outcomes framework. *International Journal of Epidemiology*, **2015**, 44, 1452-9	7.8	34
87	Standardized binomial models for risk or prevalence ratios and differences. *International Journal of Epidemiology*, **2015**, 44, 1660-72	7.8	47
86	Dynamic Visual Display of Treatment Response in HIV-Infected Adults. *Clinical Infectious Diseases*, **2015**, 61, e1-4	11.6	4
85	Risk. *American Journal of Epidemiology*, **2015**, 181, 246-50	3.8	48

84	Breast cancer subtypes and previously established genetic risk factors: a bayesian approach. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 84-97	4	29
83	Validity of US norms for the Bayley Scales of Infant Development-III in Malawian children. *European Journal of Paediatric Neurology*, **2014**, 18, 223-30	3.8	33
82	African American race and HIV virological suppression: beyond disparities in clinic attendance. *American Journal of Epidemiology*, **2014**, 179, 1484-92	3.8	25
81	Maximum likelihood, profile likelihood, and penalized likelihood: a primer. *American Journal of Epidemiology*, **2014**, 179, 252-60	3.8	93
80	Worth the weight: using inverse probability weighted Cox models in AIDS research. *AIDS Research and Human Retroviruses*, **2014**, 30, 1170-7	1.6	43
79	The role of at-risk alcohol/drug use and treatment in appointment attendance and virologic suppression among HIV(+) African Americans. *AIDS Research and Human Retroviruses*, **2014**, 30, 233-40	1.6	17
78	The parametric g-formula for time-to-event data: intuition and a worked example. *Epidemiology*, **2014**, 25, 889-97	3.1	88
77	Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence. *Aids*, **2014**, 28, 979-87	3.5	15
76	Estimating the effect of cumulative occupational asbestos exposure on time to lung cancer mortality: using structural nested failure-time models to account for healthy-worker survivor bias. *Epidemiology*, **2014**, 25, 246-54	3.1	22
75	Hospital-acquired Clostridium difficile infections: estimating all-cause mortality and length of stay. *Epidemiology*, **2014**, 25, 570-5	3.1	46
74	Association between unprotected ultraviolet radiation exposure and recurrence of ocular herpes simplex virus. *American Journal of Epidemiology*, **2014**, 179, 208-15	3.8	20
73	Assessment and indirect adjustment for confounding by smoking in cohort studies using relative hazards models. *American Journal of Epidemiology*, **2014**, 180, 933-40	3.8	26
72	Loss to clinic and five-year mortality among HIV-infected antiretroviral therapy initiators. *PLoS ONE*, **2014**, 9, e102305	3.7	11
71	Assessing the component associations of the healthy worker survivor bias: occupational asbestos exposure and lung cancer mortality. *Annals of Epidemiology*, **2013**, 23, 334-41	6.4	20
70	Serum uric acid in relation to endogenous reproductive hormones during the menstrual cycle: findings from the BioCycle study. *Human Reproduction*, **2013**, 28, 1853-62	5.7	65
69	An information criterion for marginal structural models. *Statistics in Medicine*, **2013**, 32, 1383-93	2.3	28
68	Joint effects of alcohol consumption and high-risk sexual behavior on HIV seroconversion among men who have sex with men. *Aids*, **2013**, 27, 815-23	3.5	51
67	Causal inference in occupational epidemiology: accounting for the healthy worker effect by using structural nested models. *American Journal of Epidemiology*, **2013**, 178, 1681-6	3.8	27

66	Analysis of occupational asbestos exposure and lung cancer mortality using the g formula. *American Journal of Epidemiology*, **2013**, 177, 989-96	3.8	45
65	Sensitivity analyses for sparse-data problems-using weakly informative bayesian priors. *Epidemiology*, **2013**, 24, 233-9	3.1	23
64	Accuracy loss due to selection bias in cohort studies with left truncation. *Paediatric and Perinatal Epidemiology*, **2013**, 27, 491-502	2.7	59
63	Association of early HIV viremia with mortality after HIV-associated lymphoma. *Aids*, **2013**, 27, 2365-73	3.5	29
62	The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. *Statistics in Medicine*, **2012**, 31, 2000-9	2.3	68
61	A simulation study of finite-sample properties of marginal structural Cox proportional hazards models. *Statistics in Medicine*, **2012**, 31, 2098-109	2.3	16
60	Aspirin in the primary prevention of cardiovascular disease in the Women's Health Study: effect of noncompliance. *European Journal of Epidemiology*, **2012**, 27, 431-8	12.1	11
59	Bayesian posterior distributions without Markov chains. *American Journal of Epidemiology*, **2012**, 175, 368-75	3.8	18
58	Estimating the effects of multiple time-varying exposures using joint marginal structural models: alcohol consumption, injection drug use, and HIV acquisition. *Epidemiology*, **2012**, 23, 574-82	3.1	25
57	Marginal structural models for case-cohort study designs to estimate the association of antiretroviral therapy initiation with incident AIDS or death. *American Journal of Epidemiology*, **2012**, 175, 381-90	3.8	14
56	A Statistical Appraisal of Biomarker Selection Methods Applicable to HIV/AIDS Research. *Handbook of Statistics*, **2012**, 99-128	0.6	
55	A prospective study of alcohol consumption and HIV acquisition among injection drug users. *Aids*, **2011**, 25, 221-8	3.5	20
54	A comparison of methods to estimate the hazard ratio under conditions of time-varying confounding and nonpositivity. *Epidemiology*, **2011**, 22, 718-23	3.1	19
53	Splines for trend analysis and continuous confounder control. *Epidemiology*, **2011**, 22, 874-5	3.1	114
52	The role of the c-statistic in variable selection for propensity score models. *Pharmacoepidemiology and Drug Safety*, **2011**, 20, 317-20	2.6	97
51	Limitation of inverse probability-of-censoring weights in estimating survival in the presence of strong selection bias. *American Journal of Epidemiology*, **2011**, 173, 569-77	3.8	60
50	Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. *Clinical Infectious Diseases*, **2011**, 53, 927-35	11.6	103
49	Hormonal contraception and HIV risk: evaluating marginal-structural-model assumptions. *Epidemiology*, **2011**, 22, 877-8	3.1	4

48	Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2. *Aids*, **2011**, 25, 1265-9	3.5	21
47	The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study. *PLoS Medicine*, **2011**, 8, e1001044	11.6	87
46	Pregnancy and virologic response to antiretroviral therapy in South Africa. *PLoS ONE*, **2011**, 6, e22778	3.7	19
45	Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. *American Journal of Epidemiology*, **2010**, 171, 198-205	3.8	73
44	Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial. *American Journal of Epidemiology*, **2010**, 172, 107-15	3.8	251
43	Illustrating bias due to conditioning on a collider. *International Journal of Epidemiology*, **2010**, 39, 417-20	7.8	479
42	Time scale and adjusted survival curves for marginal structural cox models. *American Journal of Epidemiology*, **2010**, 171, 691-700	3.8	50
41	Invited commentary: positivity in practice. *American Journal of Epidemiology*, **2010**, 171, 674-7; discussion 678-81	3.8	202
40	Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death. *American Journal of Epidemiology*, **2010**, 171, 113-22	3.8	21
39	Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007. *AIDS Research and Human Retroviruses*, **2010**, 26, 875-81	1.6	36
38	Neighborhood poverty and injection cessation in a sample of injection drug users. *American Journal of Epidemiology*, **2010**, 171, 391-8	3.8	57
37	Determinants of alcohol consumption in HIV-uninfected injection drug users. *Drug and Alcohol Dependence*, **2010**, 111, 173-6	4.9	13
36	Linear regression with an independent variable subject to a detection limit. *Epidemiology*, **2010**, 21 Suppl 4, S17-24	3.1	55
35	Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. *Aids*, **2010**, 24, 1341-9	3.5	37
34	Effects of time-varying exposures adjusting for time-varying confounders: the case of alcohol consumption and risk of incident human immunodeficiency virus infection. *International Journal of Public Health*, **2010**, 55, 227-8		9
33	Invited Commentary: Causal diagrams and measurement bias. *American Journal of Epidemiology*, **2009**, 170, 959-62; discussion 963-4	3.8	111
32	Effect of highly active antiretroviral therapy on incident AIDS using calendar period as an instrumental variable. *American Journal of Epidemiology*, **2009**, 169, 1124-32	3.8	25
31	Applying Quantitative Bias Analysis to Epidemiologic Data: By Timothy L. Lash, Matthew P. Fox, and Aliza K. Fink. *American Journal of Epidemiology*, **2009**, 170, 1316-1317	3.8	0

30	Estimating the odds ratio when exposure has a limit of detection. *International Journal of Epidemiology*, **2009**, 38, 1674-80	7.8	73
29	Nonparametric estimator of relative time with application to the Acyclovir Prevention Trial. *Clinical Trials*, **2009**, 6, 320-8	2.2	2
28	Time-modified confounding. *American Journal of Epidemiology*, **2009**, 170, 687-94	3.8	39
27	Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death. *Statistics in Medicine*, **2009**, 28, 1725-38	2.3	65
26	Competing risk regression models for epidemiologic data. *American Journal of Epidemiology*, **2009**, 170, 244-56	3.8	728
25	Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. *Lancet, The*, **2009**, 373, 1352-63	40	580
24	The consistency statement in causal inference: a definition or an assumption?. *Epidemiology*, **2009**, 20, 3-5	3.1	220
23	Overadjustment bias and unnecessary adjustment in epidemiologic studies. *Epidemiology*, **2009**, 20, 488-95	3.1	1108
22	Constructing inverse probability weights for marginal structural models. *American Journal of Epidemiology*, **2008**, 168, 656-64	3.8	1424
21	Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence. *Aids*, **2008**, 22, 1869-73	3.5	22
20	Confidence intervals for biomarker-based human immunodeficiency virus incidence estimates and differences using prevalent data. *American Journal of Epidemiology*, **2007**, 165, 94-100	3.8	9
19	Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. *American Journal of Epidemiology*, **2007**, 166, 219-27	3.8	48
18	Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. *Aids*, **2007**, 21, 1739-45	3.5	134
17	Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters. *American Journal of Epidemiology*, **2006**, 163, 310-5	3.8	26
16	Multiple-imputation for measurement-error correction. *International Journal of Epidemiology*, **2006**, 35, 1074-81	7.8	145
15	Survival analysis for recurrent event data: an application to childhood infectious diseases. *Statistics in Medicine*, **2006**, 25, 1431-3; author reply 1433	2.3	3
14	Sample size and statistical power assessing the effect of interventions in the context of mixture distributions with detection limits. *Statistics in Medicine*, **2006**, 25, 2647-57	2.3	8
13	Effect of acyclovir on herpetic ocular recurrence using a structural nested model. *Contemporary Clinical Trials*, **2005**, 26, 300-10	2.3	25

12	The effect of HIV infection on overdose mortality. *Aids*, **2005**, 19, 935-42	3.5	39
11	Structural accelerated failure time models for survival analysis in studies with time-varying treatments. *Pharmacoepidemiology and Drug Safety*, **2005**, 14, 477-91	2.6	123
10	Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. *American Journal of Epidemiology*, **2005**, 162, 471-8	3.8	92
9	Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy. *Aids*, **2004**, 18, 1579-84	3.5	15
8	Adjusted survival curves with inverse probability weights. *Computer Methods and Programs in Biomedicine*, **2004**, 75, 45-9	6.9	481
7	Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. *Statistics in Medicine*, **2004**, 23, 3351-63	2.3	33
6	Sample Size Calculations for the Mean in a Two Component Nonstandard Mixture Distribution. *Biometrical Journal*, **2004**, 46, 565-571	1.5	4
5	Estimation of cumulative odds ratios. *Annals of Epidemiology*, **2004**, 14, 172-8	6.4	7
4	Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. *American Journal of Epidemiology*, **2003**, 158, 687-94	3.8	203
3	Fallibility in estimating direct effects. *International Journal of Epidemiology*, **2002**, 31, 163-5	7.8	432
2	Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the PhysiciansPHealth Study. *American Journal of Epidemiology*, **2002**, 155, 1045-53	3.8	78
1	The use of propensity scores to assess the generalizability of results from randomized trials. *Journal of the Royal Statistical Society Series A: Statistics in Society*, **2001**, 174, 369-386	2.1	235